The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion

Indian Journal of Cancer

Volumn 51, Issue 7, 2014, Pages e82-e85

  Chen, D ^a   Li, X ^a   Zhao, H ^a   Fu, Y ^a   Yao, F ^a   Hu, J ^a   Du, N ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bevacizumab; intrapleural chemotherapy; malignant pleural effusion; malignant pleural mesothelioma; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CISPLATIN; PEMETREXED; VASCULOTROPIN; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY;

AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; FATIGUE; FEMALE; HEMOPTYSIS; HUMAN; HYPERTENSION; MALE; MALIGNANT PLEURA EFFUSION; NAUSEA AND VOMITING; NEUTROPENIA; PLEURA MESOTHELIOMA; TREATMENT RESPONSE; ADULT; ANALOGS AND DERIVATIVES; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; PROGNOSIS; SURVIVAL RATE;

EID: 84926327497     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.154058     Document Type: Article

References (15)

1. Ambrogi V, Mineo TC. Clinical and biologic prognostic factors in malignant pleural mesothelioma. Thorac Cancer 2012;3:289-302.
2. Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 2005;25:600-4.
3. Leung L, Hsin M, Lam KC. Management of malignant pleural effusion: Options and recommended approaches. Thorac Cancer 2013;4:9-13.
4. Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med 2005;353:740-1.
5. Teixeira LR, Vargas FS, Acencio MM, Ribeiro SC, Sales RK, Antonangelo L, et al. Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis. Lung Cancer 2011;74:392-5.
6. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A 2006;103:10397-402.
7. Musani AI. Treatment options for malignant pleural effusion. Curr Opin Pulm Med 2009;15:380-7.
8. Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med 2011;105:137-42.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
10. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443-8.
11. Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19:370-3.
12. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113:808-14.
13. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012;30:2509-15.
14. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011;72:73-7.
15. Du N, Li X, Li F, Zhao H, Fan Z, Ma J, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep 2013;29:2332-40.